High Dose Rate Transurethral Brachytherapy as a Boost Dose for Localized Adenocarcinoma of the Prostate
作者:
Meltem Serin,
Haldun Şükrü Erkal,
Serpil Dizbay Sak,
Ahmet Çakmak,
Orhan Göğüş,
Abdül Akkaya,
期刊:
Urologia Internationalis
(Karger Available online 1997)
卷期:
Volume 58,
issue 1
页码: 30-33
ISSN:0042-1138
年代: 1997
DOI:10.1159/000282941
出版商: S. Karger AG
关键词: Adenocarcinoma;prostate;High dose rate transurethral brachytherapy;Prostate-specific antigen;Radiotherapy;prostate adenocarcinoma
数据来源: Karger
摘要:
From September 1989 to February 1993, 11 patients with localized adenocarcinoma of the prostate were treated with pelvic external-beam radiation therapy followed by high dose rate (HDR) transurethral brachytherapy as a boost dose. External-beam radiation therapy was administered through opposed pelvic fields using a 60Co teletherapy unit to a tumor dose of 46–50 Gy in 23–25 fractions and followed by three fractions of transurethral brachytherapy, delivered using a 60Co HDR remote afterloading equipment. The treatment time was calculated using the prostatic capsule as the reference point. The dose calculated to be delivered to the capsule was 5 Gy/fraction, making a total of 15 Gy. The follow-up period ranged from 11 to 65 months, with a median follow-up time of 30 months. Local control was achieved in all patients. The prostate-specific antigen levels were normalized within 3 months of radiotherapy in 9 patients and within 3–6 months in the remaining 2. Transurethral brachytherapy appears to be a simple and feasible form of brachytherapy. Preliminary local control and radiotherapy-related morbidity rates are comparable to those of other forms of brachytherapy. Further follow-up is required for assessment of long-term local control and delayed radiotherapy-related morb
点击下载:
PDF
(1848KB)
返 回